

0590  
0573

# 7



ENTERED

OIPE

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/020,436A

DATE: 05/16/2002

TIME: 17:02:30

Input Set : A:\179-54.app

Output Set: N:\CRF3\05162002\J020436A.raw

```

3 <110> APPLICANT: CLARK, JONATHAN
4   LAMONT, ALAN
5   WILLIAMS, DAVID
7 <120> TITLE OF INVENTION: A METHOD FOR MAPPING THE ACTIVE SITES BOUND BY ENZYMES
8   THAT COVALENTLY MODIFY SUBSTRATE MOLECULES
10 <130> FILE REFERENCE: 179-54
12 <140> CURRENT APPLICATION NUMBER: 10/020,436A
C--> 13 <141> CURRENT FILING DATE: 2002-05-16
15 <150> PRIOR APPLICATION NUMBER: 09/530,431
16 <151> PRIOR FILING DATE: 2000-07-26
18 <150> PRIOR APPLICATION NUMBER: PCT/GB98/03259
19 <151> PRIOR FILING DATE: 1998-10-30
21 <150> PRIOR APPLICATION NUMBER: GB 9722818.3
22 <151> PRIOR FILING DATE: 1997-10-30
24 <160> NUMBER OF SEQ ID NOS: 19
26 <170> SOFTWARE: PatentIn Ver. 2.1
28 <210> SEQ ID NO: 1
29 <211> LENGTH: 8
30 <212> TYPE: PRT
31 <213> ORGANISM: Artificial Sequence
33 <220> FEATURE:
34 <223> OTHER INFORMATION: Description of Artificial Sequence: Consensus
35   peptide
W--> 37 <222> LOCATION:
38 <223> OTHER INFORMATION: Biotin-epsilon-aminohexanoic acid is linked to the
39   aspartic acid residue at position 1
41 <220> FEATURE:
42 <221> NAME/KEY: MOD_RES
W--> 43 <222> LOCATION: (8)
44 <223> OTHER INFORMATION: Norleucine
W--> 46 <400> 1
W--> 47 Asp Glu Glu Asp Tyr Phe Glu Xaa
48   1           5
51 <210> SEQ ID NO: 2
52 <211> LENGTH: 36
53 <212> TYPE: DNA
54 <213> ORGANISM: Artificial Sequence
56 <220> FEATURE:
57 <223> OTHER INFORMATION: Description of Artificial Sequence: Primer
59 <400> SEQUENCE: 2
60 ccgggatccg ccatgcccac ggacacgagc gtgtat
63 <210> SEQ ID NO: 3
64 <211> LENGTH: 57

```

36

## RAW SEQUENCE LISTING

DATE: 05/16/2002

PATENT APPLICATION: US/10/020,436A

TIME: 17:02:30

Input Set : A:\179-54.app

Output Set: N:\CRF3\05162002\J020436A.raw

```

65 <212> TYPE: DNA
66 <213> ORGANISM: Artificial Sequence
68 <220> FEATURE:
69 <223> OTHER INFORMATION: Description of Artificial Sequence: Primer
71 <400> SEQUENCE: 3
72 gggggatcct cagtgggtggt ggtgggtggtg ggcacaggca gcctcagcct tctgtgt      57
75 <210> SEQ ID NO: 4
76 <211> LENGTH: 5
77 <212> TYPE: PRT
78 <213> ORGANISM: Artificial Sequence
80 <220> FEATURE:
81 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
83 <400> SEQUENCE: 4
84 Asp Glu Glu Asp Tyr
85   1           5
88 <210> SEQ ID NO: 5
89 <211> LENGTH: 5
90 <212> TYPE: PRT
91 <213> ORGANISM: Artificial Sequence
93 <220> FEATURE:
94 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
96 <400> SEQUENCE: 5
97 Asp Glu Glu Tyr Phe
98   1           5
101 <210> SEQ ID NO: 6
102 <211> LENGTH: 5
103 <212> TYPE: PRT
104 <213> ORGANISM: Artificial Sequence
106 <220> FEATURE:
107 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
109 <400> SEQUENCE: 6
110 Asp Glu Tyr Glu Phe
111   1           5
114 <210> SEQ ID NO: 7
115 <211> LENGTH: 5
116 <212> TYPE: PRT
117 <213> ORGANISM: Artificial Sequence
119 <220> FEATURE:
120 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide
122 <220> FEATURE:
123 <221> NAME/KEY: MOD_RES
124 <222> LOCATION: (5)
125 <223> OTHER INFORMATION: Norleucine
127 <400> SEQUENCE: 7
W--> 128 Asp Tyr Phe Glu Xaa
129   1           5
132 <210> SEQ ID NO: 8
133 <211> LENGTH: 5
134 <212> TYPE: PRT

```

## RAW SEQUENCE LISTING

DATE: 05/16/2002

PATENT APPLICATION: US/10/020,436A

TIME: 17:02:30

Input Set : A:\179-54.app

Output Set: N:\CRF3\05162002\J020436A.raw

135 <213> ORGANISM: Artificial Sequence  
137 <220> FEATURE:  
138 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide  
140 <400> SEQUENCE: 8  
141 Asp Glu Glu Asp Tyr  
142 1 5  
145 <210> SEQ ID NO: 9  
146 <211> LENGTH: 5  
147 <212> TYPE: PRT  
148 <213> ORGANISM: Artificial Sequence  
150 <220> FEATURE:  
151 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide  
153 <400> SEQUENCE: 9  
154 Asp Glu Glu Tyr Asp  
155 1 5  
158 <210> SEQ ID NO: 10  
159 <211> LENGTH: 5  
160 <212> TYPE: PRT  
161 <213> ORGANISM: Artificial Sequence  
163 <220> FEATURE:  
164 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide  
166 <400> SEQUENCE: 10  
167 Asp Glu Tyr Glu Asp  
168 1 5  
171 <210> SEQ ID NO: 11  
172 <211> LENGTH: 5  
173 <212> TYPE: PRT  
174 <213> ORGANISM: Artificial Sequence  
176 <220> FEATURE:  
177 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide  
179 <400> SEQUENCE: 11  
180 Asp Tyr Glu Glu Val  
181 1 5  
184 <210> SEQ ID NO: 12  
185 <211> LENGTH: 5  
186 <212> TYPE: PRT  
187 <213> ORGANISM: Artificial Sequence  
189 <220> FEATURE:  
190 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide  
192 <220> FEATURE:  
193 <221> NAME/KEY: MOD\_RES  
194 <222> LOCATION: (5)  
195 <223> OTHER INFORMATION: Norleucine  
197 <400> SEQUENCE: 12  
W--> 198 Tyr Ser Ile Ile Xaa  
199 1 5  
202 <210> SEQ ID NO: 13  
203 <211> LENGTH: 5  
204 <212> TYPE: PRT

## RAW SEQUENCE LISTING

DATE: 05/16/2002

PATENT APPLICATION: US/10/020,436A

TIME: 17:02:30

Input Set : A:\179-54.app

Output Set: N:\CRF3\05162002\J020436A.raw

205 <213> ORGANISM: Artificial Sequence  
207 <220> FEATURE:  
208 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide  
210 <400> SEQUENCE: 13  
211 Asp Glu Glu Glu Tyr  
212 1 5  
215 <210> SEQ ID NO: 14  
216 <211> LENGTH: 5  
217 <212> TYPE: PRT  
218 <213> ORGANISM: Artificial Sequence  
220 <220> FEATURE:  
221 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide  
223 <400> SEQUENCE: 14  
224 Asp Glu Glu Tyr Phe  
225 1 5  
228 <210> SEQ ID NO: 15  
229 <211> LENGTH: 5  
230 <212> TYPE: PRT  
231 <213> ORGANISM: Artificial Sequence  
233 <220> FEATURE:  
234 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide  
236 <400> SEQUENCE: 15  
237 Asp Glu Tyr His Asn  
238 1 5  
241 <210> SEQ ID NO: 16  
242 <211> LENGTH: 5  
243 <212> TYPE: PRT  
244 <213> ORGANISM: Artificial Sequence  
246 <220> FEATURE:  
247 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide  
249 <400> SEQUENCE: 16  
250 Asp Tyr His Leu Phe  
251 1 5  
254 <210> SEQ ID NO: 17  
255 <211> LENGTH: 5  
256 <212> TYPE: PRT  
257 <213> ORGANISM: Artificial Sequence  
259 <220> FEATURE:  
260 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide  
262 <400> SEQUENCE: 17  
263 Tyr Pro Ile Glu Val  
264 1 5  
267 <210> SEQ ID NO: 18  
268 <211> LENGTH: 5  
269 <212> TYPE: PRT  
270 <213> ORGANISM: Artificial Sequence  
272 <220> FEATURE:  
273 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide  
275 <400> SEQUENCE: 18

## RAW SEQUENCE LISTING

DATE: 05/16/2002

PATENT APPLICATION: US/10/020,436A

TIME: 17:02:30

Input Set : A:\179-54.app

Output Set: N:\CRF3\05162002\J020436A.raw

276 Ser Tyr Phe His Glu  
277 1 5  
280 <210> SEQ ID NO: 19  
281 <211> LENGTH: 15  
282 <212> TYPE: PRT  
283 <213> ORGANISM: Artificial Sequence  
285 <220> FEATURE:  
286 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
287 peptide  
289 <400> SEQUENCE: 19  
290 Lys Lys Lys Lys Ala Asp Glu Glu Asp Tyr Phe Ile Pro Pro Ala  
291 1 5 10 15

RAW SEQUENCE LISTING ERROR SUMMARY  
PATENT APPLICATION: US/10/020,436A

DATE: 05/16/2002  
TIME: 17:02:31

Input Set : A:\179-54.app  
Output Set: N:\CRF3\05162002\J020436A.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 8

Seq#:7; Xaa Pos. 5

Seq#:12; Xaa Pos. 5

## VERIFICATION SUMMARY

DATE: 05/16/2002

PATENT APPLICATION: US/10/020,436A

TIME: 17:02:31

Input Set : A:\179-54.app

Output Set: N:\CRF3\05162002\J020436A.raw

L:13 M:271 C: Current Filing Date differs, Replaced Current Filing Date  
L:37 M:281 W: Numeric Fields not Ordered, <222> Sort in ascending order!  
L:46 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:1  
L:47 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0  
L:128 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:0  
L:198 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12 after pos.:0